Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Shteinfer-Kuzmine

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Cancers|December 15, 2018
Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated StatesTasleem Arif, Avijit Paul, Yakov Krelin, et al.
Molecular Oncology|April 27, 2018
Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapyAnna Shteinfer-Kuzmine, Zohar Amsalem, Tasleem Arif, et al.
Frontiers in Oncology|October 3, 2022
Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppressionSwaroop Kumar Pandey, Anna Shteinfer-Kuzmine, Vered Chalifa-Caspi, et al.
Apoptosis : an International Journal on Programmed Cell Death|September 27, 2025
VDAC1-interacting proteins: binding site mapping and their derived peptides induce apoptosis and multifaceted cellular effectsManikandan Santhanam, Venkatadri Babu, Anna Shteinfer-Kuzmine, et al.
Cells|April 12, 2024
Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder CancerBelal Alhozeel, Swaroop Kumar Pandey, Anna Shteinfer-Kuzmine, et al.
Cancers|April 26, 2020
The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic LinkZohar Amsalem, Tasleem Arif, Anna Shteinfer-Kuzmine, et al.
Cancers|July 2, 2021
VDAC1 Silencing in Cancer Cells Leads to Metabolic Reprogramming That Modulates Tumor MicroenvironmentErez Zerbib, Tasleem Arif, Anna Shteinfer-Kuzmine, et al.
Molecular Therapy. Nucleic Acids|September 4, 2023
Overexpression of the mitochondrial anti-viral signaling protein, MAVS, in cancers is associated with cell survival and inflammationSweta Trishna, Avia Lavon, Anna Shteinfer-Kuzmine, et al.
Frontiers in Physiology|October 21, 2021
Adverse Effects of Metformin From Diabetes to COVID-19, Cancer, Neurodegenerative Diseases, and Aging: Is VDAC1 a Common Target?Varda Shoshan-Barmatz, Uttpal Anand, Edna Nahon-Crystal, et al.
Biomolecules|July 27, 2022
Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor HallmarksSwaroop Kumar Pandey, Renen Machlof-Cohen, Manikandan Santhanam, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Cancers|December 15, 2018
Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated StatesTasleem Arif, Avijit Paul, Yakov Krelin, et al.
Molecular Oncology|April 27, 2018
Selective induction of cancer cell death by VDAC1-based peptides and their potential use in cancer therapyAnna Shteinfer-Kuzmine, Zohar Amsalem, Tasleem Arif, et al.
Frontiers in Oncology|October 3, 2022
Non-apoptotic activity of the mitochondrial protein SMAC/Diablo in lung cancer: Novel target to disrupt survival, inflammation, and immunosuppressionSwaroop Kumar Pandey, Anna Shteinfer-Kuzmine, Vered Chalifa-Caspi, et al.
Apoptosis : an International Journal on Programmed Cell Death|September 27, 2025
VDAC1-interacting proteins: binding site mapping and their derived peptides induce apoptosis and multifaceted cellular effectsManikandan Santhanam, Venkatadri Babu, Anna Shteinfer-Kuzmine, et al.
Cells|April 12, 2024
Silencing the Mitochondrial Gatekeeper VDAC1 as a Potential Treatment for Bladder CancerBelal Alhozeel, Swaroop Kumar Pandey, Anna Shteinfer-Kuzmine, et al.
Cancers|April 26, 2020
The Mitochondrial Protein VDAC1 at the Crossroads of Cancer Cell Metabolism: The Epigenetic LinkZohar Amsalem, Tasleem Arif, Anna Shteinfer-Kuzmine, et al.
Cancers|July 2, 2021
VDAC1 Silencing in Cancer Cells Leads to Metabolic Reprogramming That Modulates Tumor MicroenvironmentErez Zerbib, Tasleem Arif, Anna Shteinfer-Kuzmine, et al.
Molecular Therapy. Nucleic Acids|September 4, 2023
Overexpression of the mitochondrial anti-viral signaling protein, MAVS, in cancers is associated with cell survival and inflammationSweta Trishna, Avia Lavon, Anna Shteinfer-Kuzmine, et al.
Frontiers in Physiology|October 21, 2021
Adverse Effects of Metformin From Diabetes to COVID-19, Cancer, Neurodegenerative Diseases, and Aging: Is VDAC1 a Common Target?Varda Shoshan-Barmatz, Uttpal Anand, Edna Nahon-Crystal, et al.
Biomolecules|July 27, 2022
Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor HallmarksSwaroop Kumar Pandey, Renen Machlof-Cohen, Manikandan Santhanam, et al.
Pageof 4